HBW
DGX icon

Hazlett, Burt & Watson’s Quest Diagnostics DGX Stock Holding History

Hazlett, Burt & Watson’s Portfolio DGX Stock Details DGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$13K Hold
60
– – ﹤0.01% 655
2026
Q1 		$12K Hold
60
– – ﹤0.01% 661
2025
Q4 		$11K Buy
60
+27
+82% +$4.92K ﹤0.01% 687
2025
Q3 		$6K Buy
+33
New +$5.86K ﹤0.01% 715
2023
Q1 		– Sell
-150
Closed -$23K – 627
2022
Q4 		$23K Hold
150
– – 0.02% 363
2022
Q3 		$18K Hold
150
– – 0.02% 389
2022
Q2 		$20K Hold
150
– – 0.02% 379
2022
Q1 		$21K Buy
+150
New +$20.9K 0.02% 386

Other funds holding DGX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Boston Partners
Boston Partners Boston, Massachusetts $113B AUM 38.87% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
EIG
EdgePoint Investment Group Toronto, Ontario, Canada $13.2B AUM 32.43% 1-Year Est. Return

Hazlett, Burt & Watson's DGX Position: Q2 2026 in Review

Hazlett, Burt & Watson held its Quest Diagnostics (DGX) position steady in Q2 2026 at 60 shares worth $13K. The position accounts for ﹤0.01% of the portfolio, ranked #655.

Hazlett, Burt & Watson first reported a position in DGX in Q1 2022 and has held it in 8 quarters since. The position peaked at $23K in Q4 2022. 1,099 funds tracked by Wall St. Rank hold DGX as of Q2 2026.

  • Hazlett, Burt & Watson held 60 shares of Quest Diagnostics worth $13K as of Q2 2026.
  • Hazlett, Burt & Watson left its Quest Diagnostics share count unchanged in Q2 2026.
  • Quest Diagnostics made up ﹤0.01% of Hazlett, Burt & Watson's portfolio in Q2 2026, its #655 holding.
  • Hazlett, Burt & Watson first reported a position in Quest Diagnostics in Q1 2022 and has held it in 8 quarters since.
  • Hazlett, Burt & Watson's Quest Diagnostics position peaked at $23K in Q4 2022.
  • 1,099 funds tracked by Wall St. Rank held Quest Diagnostics as of Q2 2026.

Based on Hazlett, Burt & Watson's 13F filing for Q2 2026, filed 30 Jul 2026.